Cambridge Biotech Company Claims Breakthrough On New Class Of 'Gene-Silencing' Drugs

Stock in the Cambridge pharmaceutical company, Alnylam, is soaring due to expectations it may have successfully tested a so-called "RNAI" drug that could treat a rare malfunction of the nervous system. Luke Timmerman, who writes the bio-tech newsletter "The Timmerman Report," joined Morning Edition.